CD163 and lung carcinoma: Our results from the NSCLC discovery cohort were validated by single-cell sequencing of three lung carcinomas (10) where LAIR-1 was highly expressed on CK8/CK10+ tumor cells and CD68+ and CD163+ macrophages (Supplementary Fig. S3A and S3B).